|
Status |
Public on Oct 07, 2009 |
Title |
LOX1 oxLDL 6hr 282295703 |
Sample type |
RNA |
|
|
Source name |
LOX1_oxLDL_6hr
|
Organism |
Homo sapiens |
Characteristics |
Extract:LOX-1:221303 Extract Description:LOX1_oxLDL_6hr:221303 Quality: Classification:Medium Quality: Gradient Severity:0.06 Quality: Distortion Severity:0.03 Quality: Defective Area (%):0 Quality: Outlier Area (%):0.01 Quality: 3'/5' Mean:1.51 Quality: Background Mean Dev.:0.77 Quality: Absent (%):59.52 Quality: Absent (%) Dev.:0.98 Quality: Scaling Factor:0.87 Quality: Scaling Factor Dev.:2.24 Pretreatment [C]:LOX1 Time point [C]:6 hours Treatment [C]:Oxidized LDL Genomic ID [C]:221303 Cell name [C]:HAECT Treatment amount [C]:50 ug/ml Cell type [C]:Endothelial Organism species [C]:Human:Homo sapiens Cohort name [C]:LOX1_oxLDL_6hr RNA extraction source key [A]:282295703
|
Extracted molecule |
polyA RNA |
Extraction protocol |
RNA was extracted from HAECT cells
|
Label |
biotin
|
Label protocol |
Affymetrix in-vitro labeling protocol
|
|
|
Hybridization protocol |
Affymetrix standard hybridization protocol
|
Scan protocol |
Affymetrix standard scan protocol
|
Description |
LOX1_oxLDL_6hr:221303
|
Data processing |
Affymetrix MAS 5.0 algorithm
|
|
|
Submission date |
Oct 09, 2008 |
Last update date |
Oct 07, 2009 |
Contact name |
Andrew Hill |
E-mail(s) |
andrew.hill@pfizer.com
|
Phone |
617-674-6341
|
Organization name |
Pfizer
|
Department |
Research Business Technology
|
Street address |
300 Technology Square
|
City |
Cambridge |
State/province |
MA |
ZIP/Postal code |
02139 |
Country |
USA |
|
|
Platform ID |
GPL570 |
Series (1) |
GSE13139 |
LOX-1-dependent transcriptional regulation after oxidized LDL (OxLDL) treatment of human aortic endothelial cells. |
|